Tenderwize
Back to tender search

Pharmaceuticals with active substance Erythropoietin (ATC: B03XA01 - strength over 10,000 IU per dosage unit)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Aug 30, 2026 · 13 days left·Open·Supplies
Original notice title

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Erythropoietin (ATC: B03XA01 - in der Wirkstärke über 10.000 IE je Dosiereinheit)

70/100

Opportunity Score

PromisingLow complexity
SuppliesOpen
Why this score?

Opportunity

70 / 100

Complexity

20 / 100

Risk factors

AOK may terminate agreements early if exclusive contracts are tendered for the same active substance during the contrac...

No guaranteed volume; actual sales depend on prescription behavior and number of participants.

Submission deadline in 13 days

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Strong opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Supply of Erythropoietin pharmaceuticals (ATC B03XA01, >10,000 IU per dose unit) under non-exclusive discount agreements.
  • Open-house model allowing any eligible pharmaceutical company to participate at any time.
Show full summary

This is an open-house model for non-exclusive discount agreements on Erythropoietin pharmaceuticals (strength >10,000 IU per dose unit) with AOK Sachsen-Anhalt. Any eligible pharmaceutical company can conclude a contract at any time under uniform conditions. The contract runs from earliest 01.11.2024 to 31.10.2026 (max 24 months). No estimated value or guaranteed volume is provided. The tender is not a public procurement under GWB but published for transparency.

Risks

AOK may terminate agreements early if exclusive contracts are tendered for the same active substance during the contrac...

No guaranteed volume; actual sales depend on prescription behavior and number of participants.

Submission deadline in 13 days

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical company or consortium of pharmaceutical companies.

Administrative

  • Must request and submit completed participation documents and signed contract.
  • Must meet uniform contract conditions (not specified in detail).

Award Criteria

Lot 1

No competitive award; contract available to all eligible participants.

Buyer

Location

Magdeburg, DEU

Buyer profile

Open profile

Identifier

DE258393558

Activity

Health

Lots (1)

LOT-0001

Pharmaceuticals with active substance Erythropoietin (ATC: B03XA01 - strength over 10,000 IU per dosage unit)

Conclusion of non-exclusive discount agreements for finished medicinal products containing Erythropoietin (ATC: B03XA01, strength >10,000 IU) under an open-house model. Any eligible pharmaceutical company can join at any time with standard contract terms. No exclusivity.

SuppliesEU fundedElectronic submission

Location

DEE03, Germany

Duration

2 YEAR

Category

Pharmaceutical products

Award Criteria

No competitive award; contract available to all eligible participants.

Deadline

Deadline Aug 30, 2026

Procurement Details

Publication date
19 Sep 2024
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
567828-2024

Documents (1)

Similar tenders